[Form 4] Avanos Medical, Inc. Insider Trading Activity
John Joseph Hurley, Principal Accounting Officer of Avanos Medical, Inc. (AVNS), reported a Form 4 disclosing a tax-withholding sale tied to vested restricted stock units. On 09/05/2025 the filing shows 345 shares were disposed of at $12.66 per share under transaction code F(1). The filing explains these shares were surrendered to the issuer to satisfy tax withholding on time-based restricted share units awarded on 09/05/2024. After the transaction, Hurley beneficially owns 11,364 shares directly. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
John Joseph Hurley, Principal Accounting Officer di Avanos Medical, Inc. (AVNS), ha presentato un Modulo 4 che riporta una vendita per ritenuta fiscale collegata a unità azionarie ristrette maturate. Il documento indica che il 05/09/2025 sono state cedute 345 azioni a $12,66 per azione con codice transazione F(1). Nel modulo si precisa che queste azioni sono state consegnate all’emittente per soddisfare la ritenuta fiscale sulle restricted share units a maturazione temporale assegnate il 05/09/2024. Dopo l’operazione, Hurley possiede direttamente in modo vantaggioso 11.364 azioni. Il Modulo 4 è stato firmato da un procuratore il 09/09/2025.
John Joseph Hurley, Principal Accounting Officer de Avanos Medical, Inc. (AVNS), presentó un Formulario 4 que revela una venta por retención de impuestos relacionada con unidades restringidas de acciones que ya vencieron. El registro muestra que el 05/09/2025 se dispusieron 345 acciones a $12.66 por acción bajo el código de transacción F(1). El formulario explica que estas acciones se entregaron al emisor para cubrir la retención fiscal de las restricted share units por vencimiento temporal otorgadas el 05/09/2024. Tras la transacción, Hurley posee beneficiariamente de forma directa 11.364 acciones. El Formulario 4 fue firmado por un apoderado el 09/09/2025.
John Joseph Hurley, Avanos Medical, Inc. (AVNS)의 Principal Accounting Officer는 소득세 원천징수 처리와 관련된 확정된 제한부 주식유닛(vested RSU)의 매각을 공시한 Form 4를 제출했습니다. 제출서류에 따르면 2025-09-05에 거래코드 F(1)로 345주가 주당 $12.66에 처분되었습니다. 해당 서류는 이 주식들이 2024-09-05에 부여된 기간 기반 restricted share units의 세금 원천징수를 충당하기 위해 발행사에 반환되었다고 설명합니다. 거래 후 Hurley는 직접적으로 유익소유권을 통해 11,364주를 보유하고 있습니다. Form 4는 2025-09-09에 법정대리인(또는 위임권자)에 의해 서명되었습니다.
John Joseph Hurley, Principal Accounting Officer d'Avanos Medical, Inc. (AVNS), a déposé un Formulaire 4 divulguant une vente pour prélèvement fiscal liée à des unités d'actions restreintes acquises. Le dossier indique que le 05/09/2025 345 actions ont été cédées à 12,66 $ par action sous le code de transaction F(1). Le formulaire précise que ces actions ont été remises à l'émetteur pour satisfaire la retenue d'impôt sur des restricted share units à vesting temporel attribuées le 05/09/2024. Après la transaction, Hurley détient directement à titre bénéficiaire 11 364 actions. Le Formulaire 4 a été signé par un mandataire le 09/09/2025.
John Joseph Hurley, Principal Accounting Officer von Avanos Medical, Inc. (AVNS), meldete ein Formular 4, das einen steuerlich bedingten Verkauf im Zusammenhang mit bereits ausgefallenen Restricted Stock Units offenlegt. In der Einreichung heißt es, dass am 05.09.2025 345 Aktien zu $12,66 pro Aktie unter Transaktionscode F(1) veräußert wurden. Das Formular erklärt, dass diese Aktien zur Begleichung der Steuerabzüge für am 05.09.2024 gewährte zeitbasierte Restricted Share Units an den Emittenten zurückgegeben wurden. Nach der Transaktion besitzt Hurley unmittelbar wirtschaftlich 11.364 Aktien. Das Formular 4 wurde am 09.09.2025 von einem Bevollmächtigten unterzeichnet.
- Proper disclosure of the transaction on Form 4 demonstrating compliance with Section 16 reporting requirements
- Transaction tied to tax withholding on vested TRSUs, indicating a routine administrative sale rather than an opportunistic insider sale
- None.
Insights
TL;DR: Routine insider tax-withholding sale on vested RSUs; shows compliance with disclosure and tax obligations.
The Form 4 reports a non-discretionary disposition of 345 shares to satisfy withholding on vested time-based restricted share units granted a year earlier. This is a common, non-strategic transaction that reduces the insider's net share count but does not indicate a change in company control or executive intent to liquidate holdings. The use of an attorney-in-fact for signature is procedural and acceptable when properly authorized.
TL;DR: Small, routine disposition; immaterial to company capitalization and likely unrelated to trading strategy.
Transaction details: 345 shares sold at $12.66 per share on 09/05/2025, leaving 11,364 shares beneficially owned. The sale is explicitly tied to tax withholding for TRSUs awarded 09/05/2024, indicating the transaction is administrative rather than a market-driven divestiture. Given the modest size relative to typical insider holdings, the market impact is likely negligible.
John Joseph Hurley, Principal Accounting Officer di Avanos Medical, Inc. (AVNS), ha presentato un Modulo 4 che riporta una vendita per ritenuta fiscale collegata a unità azionarie ristrette maturate. Il documento indica che il 05/09/2025 sono state cedute 345 azioni a $12,66 per azione con codice transazione F(1). Nel modulo si precisa che queste azioni sono state consegnate all’emittente per soddisfare la ritenuta fiscale sulle restricted share units a maturazione temporale assegnate il 05/09/2024. Dopo l’operazione, Hurley possiede direttamente in modo vantaggioso 11.364 azioni. Il Modulo 4 è stato firmato da un procuratore il 09/09/2025.
John Joseph Hurley, Principal Accounting Officer de Avanos Medical, Inc. (AVNS), presentó un Formulario 4 que revela una venta por retención de impuestos relacionada con unidades restringidas de acciones que ya vencieron. El registro muestra que el 05/09/2025 se dispusieron 345 acciones a $12.66 por acción bajo el código de transacción F(1). El formulario explica que estas acciones se entregaron al emisor para cubrir la retención fiscal de las restricted share units por vencimiento temporal otorgadas el 05/09/2024. Tras la transacción, Hurley posee beneficiariamente de forma directa 11.364 acciones. El Formulario 4 fue firmado por un apoderado el 09/09/2025.
John Joseph Hurley, Avanos Medical, Inc. (AVNS)의 Principal Accounting Officer는 소득세 원천징수 처리와 관련된 확정된 제한부 주식유닛(vested RSU)의 매각을 공시한 Form 4를 제출했습니다. 제출서류에 따르면 2025-09-05에 거래코드 F(1)로 345주가 주당 $12.66에 처분되었습니다. 해당 서류는 이 주식들이 2024-09-05에 부여된 기간 기반 restricted share units의 세금 원천징수를 충당하기 위해 발행사에 반환되었다고 설명합니다. 거래 후 Hurley는 직접적으로 유익소유권을 통해 11,364주를 보유하고 있습니다. Form 4는 2025-09-09에 법정대리인(또는 위임권자)에 의해 서명되었습니다.
John Joseph Hurley, Principal Accounting Officer d'Avanos Medical, Inc. (AVNS), a déposé un Formulaire 4 divulguant une vente pour prélèvement fiscal liée à des unités d'actions restreintes acquises. Le dossier indique que le 05/09/2025 345 actions ont été cédées à 12,66 $ par action sous le code de transaction F(1). Le formulaire précise que ces actions ont été remises à l'émetteur pour satisfaire la retenue d'impôt sur des restricted share units à vesting temporel attribuées le 05/09/2024. Après la transaction, Hurley détient directement à titre bénéficiaire 11 364 actions. Le Formulaire 4 a été signé par un mandataire le 09/09/2025.
John Joseph Hurley, Principal Accounting Officer von Avanos Medical, Inc. (AVNS), meldete ein Formular 4, das einen steuerlich bedingten Verkauf im Zusammenhang mit bereits ausgefallenen Restricted Stock Units offenlegt. In der Einreichung heißt es, dass am 05.09.2025 345 Aktien zu $12,66 pro Aktie unter Transaktionscode F(1) veräußert wurden. Das Formular erklärt, dass diese Aktien zur Begleichung der Steuerabzüge für am 05.09.2024 gewährte zeitbasierte Restricted Share Units an den Emittenten zurückgegeben wurden. Nach der Transaktion besitzt Hurley unmittelbar wirtschaftlich 11.364 Aktien. Das Formular 4 wurde am 09.09.2025 von einem Bevollmächtigten unterzeichnet.